Watch RARE. Know when insiders buy.
One email the day a filing lands. Free.
RARE
Ultragenyx Pharmaceutical Inc.
15.92
−0.10 −0.62%
USD · Oct 21, 07:40 p.m. ET
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
38
FLAG · insiders 44, shorts 32
Insiders, 90 days
−$128K
net selling · 0 buys, 3 sells
Congress, 90 days
1 / 0
buys / sells · latest disclosed Oct 12
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $1.6BP/E —DIV YIELD —FCF YIELD -31.16%REV TTM $717.2M +17.5%NET INCOME −$586MNET CASH —52W 12.88 – 36.54SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $214M | +28.1% | — | −$75M | −$92M | — | -0.90 | −$97M | $1M | −$98M | Aug 5 |
| Q1 2026 · Mar 31 | $136M | −2.2% | — | −$169M | −$185M | — | -1.84 | −$197M | $1M | −$198M | May 6 |
| Q4 2025 · Dec 31derived | $207.3M | +25.9% | — | −$113.3M | −$128.6M | — | -1.28 | −$99.8M | $938K | −$100.8M | Feb 18 |
| Q3 2025 · Sep 30 | $159.9M | +14.7% | — | −$170.9M | −$180.4M | — | -1.81 | −$91.2M | $1.1M | −$92.2M | Nov 5 |
| Q2 2025 · Jun 30 | $167M | +13.6% | — | −$108M | −$115M | — | -1.17 | −$109M | $3M | −$112M | Aug 5 |
| Q1 2025 · Mar 31 | $139M | +27.7% | — | −$143M | −$151M | — | -1.57 | −$166M | $1M | −$167M | May 6 |
| Q4 2024 · Dec 31derived | $164.6M | +29.5% | — | −$122.3M | −$133.2M | — | -1.38 | −$79.3M | $163K | −$79.5M | Feb 18 |
| Q3 2024 · Sep 30 | $139.5M | +42.3% | — | −$132M | −$133.5M | — | -1.40 | −$67M | $1.6M | −$68.6M | Nov 5 |
| Q2 2024 · Jun 30 | $147M | — | — | −$116.4M | −$131.6M | — | -1.52 | −$77M | $2M | −$79M | Aug 6 |
| Q1 2024 · Mar 31 | $108.8M | — | — | −$165.3M | −$170.7M | — | -2.03 | −$190.7M | $3.2M | −$193.9M | May 7 |
| Q4 2023 · Dec 31derived | $127.1M | — | — | −$121.8M | −$123.6M | — | -1.44 | −$84.1M | $1.3M | −$85.4M | Feb 18 |
| Q3 2023 · Sep 30 | $98.1M | — | — | −$145.1M | −$159.6M | — | -2.23 | −$117.9M | $3.7M | −$121.6M | Nov 6 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $673M | — | −$535M | −$575M | -85.4% | -5.83 | −$466M | $6M | −$472M | — | — |
| FY2024 · to Dec 31 | $560M | — | −$536M | −$569M | -101.6% | -6.29 | −$414M | $7M | −$421M | — | — |
| FY2023 · to Dec 31 | $434M | — | −$569M | −$607M | -139.9% | -8.25 | −$475M | $44M | −$519M | — | — |
| FY2022 · to Dec 31 | $363.3M | — | −$648.9M | −$707.4M | -194.7% | -10.12 | −$380.5M | $116.1M | −$496.6M | — | — |
| FY2021 · to Dec 31 | $351.4M | — | −$381.7M | −$454M | -129.2% | -6.70 | −$338.7M | $73.1M | −$411.8M | — | — |
| FY2020 · to Dec 31 | $271M | — | −$330.1M | −$186.6M | -68.8% | -3.07 | −$132.2M | $43.9M | −$176.1M | — | — |
Every number comes from Ultragenyx Pharmaceutical Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.